ALK and neoplasm: Trk receptors are therefore considered an attractive target for targeted therapies, with the selective Trk inhibitor, lestaurtinib, and pan-ALK/Trk/ROS1 inhibitor, entrectinib, showing favourable preclinical and phase 1 clinical results [57,58] for relapsed/refractory neuroblastoma tumours.